The Report
Verified funding, headquarters, and leadership news from the world's most innovative businesses
10 reports and counting
Smack Technologies Raises $61M Series B for Defense AI
Smack Technologies raised a $61 million Series B led by Costanoa Ventures and First In, bringing total capital raised to more than $90 million.
MomentumCreate Platform raises $61M Series C at $213M valuation
MomentumCreate Platform secures $61M in Series C funding led by Paradigm, reaching $213M valuation as it accelerates growth in the automotive sector.
MomentumShift Networks raises $13M Series A at $61M valuation
MomentumShift Networks secures $13M in Series A funding led by Thrive Capital, reaching $61M valuation as it accelerates growth in the automotive sector.
Regard Raises $61M in Series B
Regard, a HealthTech company based in Los Angeles, CA, has raised $61M in Series B at a $320M valuation led by Oak HC/FT, TCV.
Reprieve Cardiovascular Raises $61M in Series B
Reprieve Cardiovascular, a HealthTech company based in Milford, MA, has raised $61M in Series B at a $300M valuation led by New Enterprise Associates, Sofinnova Partners.
Reprieve Cardiovascular Raises $61M Series B to Transform MedTech
Reprieve Cardiovascular has secured $61M Series B in funding to accelerate growth and innovation in the medtech sector. Cardiovascular device company developing personalized heart failure therapies and monitoring solutions...
Regard raises $61M Series B at $320M valuation
Regard raises $61M in Series B at $320M valuation. AI clinical insights platform for physicians and care teams...
Reprieve Cardiovascular raises $61M Series B at $300M valuation
Reprieve Cardiovascular raises $61M in Series B at $300M valuation. Developer of therapy for acute decompensated heart failure...
Vibrant Therapeutics Raises $61M Series B | Logic-Gated Cancer Immunotherapy
Clinical-stage biotech Vibrant Therapeutics secures $61 million Series B for tumor microenvironment-activated immunotherapies.
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.